16299242Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DWClinical cancer research : an official journal of the American Association for Cancer ResearchCarcinoma, Squamous Cell; ErbB Receptors; Head and Neck Neoplasms; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2Aged; Antineoplastic Agents; Base Sequence; DNA Mutational Analysis; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Treatment OutcomeResponse of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.Clin Cancer Res2005-11-15T00:00:002005Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000368Living Beings1341183530.29479AgedD000970Chemicals & Drugs40723510.435494Antineoplastic AgentsD002294Disorders19910750.588875Carcinoma, Squamous CellD001483Chemicals & DrugsGenes & Molecular Sequences48123290.731431Base SequenceD004252Procedures2265260.864607DNA Mutational AnalysisD008875Concepts & IdeasLiving Beings1473249570.258834Middle AgedD009154Physiology70239520.442682MutationAuthorship 283852D005260Physiology1992444050.191184FemaleD006258Disorders15210510.576809Head and Neck NeoplasmsD006801Living Beings2262862810.130064HumansD008297Physiology1931408600.201635Male0.2799370.06998433authors10.2516has subject areaD016896Concepts & Ideas101179490.402421Treatment OutcomeD011799Chemicals & Drugs652200.877248QuinazolinesD018719Chemicals & Drugs832230.868908Receptor, ErbB-2D066246Chemicals & Drugs1494850.779557ErbB ReceptorsD047428Chemicals & Drugs2065890.714226Protein Kinase InhibitorsMedicinePathologyUniversity of ChicagoEzraCohenEzra Cohen41.78927490000000-87.601250000000001350Cohen, EzraASSOCIATE PROFESSOREverett E.VokesEverett E. Vokes41.78927490000000-87.601250000000001920Vokes, Everett E.ProfessorMark W.Lingen22tnDKQbOfnamXNnYUHhvWD+6g==Mark W. Lingen41.78927490000000-87.60125000000000864Lingen, Mark W.Professortrue1ASSOCIATE PROFESSORASSOCIATE PROFESSORtrue1ProfessorProfessortrue1ProfessorProfessorAuthorship 560841Authorship 5608513